Search

Displaying results 2701 - 2710 of 10000 in total
  1. Drug

    Pitolisant

    go.drugbank.com/drugs/DB11642
    ApprovedInvestigational

    [A32022] Histaminergic neuron signalling in the brain plays a role in maintaining wakefulness; by blocking histamine autoreceptors, pitolisant enhances the activity of histaminergic neurons, as well as … In a European clinical trial of adult patients with narcolepsy, there was a reduction in the Epworth Sleepiness Scale (ESS) score from pitolisant therapy compared to placebo.

  2. Drug

    Mepenzolate

    go.drugbank.com/drugs/DB04843
    ApprovedWithdrawn

    Pharmacologically, it is a post-ganglionic parasympathetic inhibitor. … Mepenzolate is a post-ganglionic parasympathetic inhibitor. It decreases gastric acid and pepsin secretion and suppresses spontaneous contractions of the colon.

  3. Drug

    Tremelimumab

    go.drugbank.com/drugs/DB11771
    ApprovedInvestigational

    CTLA-4 is a cell surface receptor expressed on activated T cells to act as a negative regulator for T cells. … [A253717, L43652] Because CTLA-4 is an immune checkpoint that plays a vital role in regulating T cell-mediated immune response, tremelimumab is considered an immune checkpoint inhibitor, which is an emerging

  4. Drug

    Tengonermin

    go.drugbank.com/drugs/DB16689
    Investigational

    Tengonermin, also known as NGR-hTNF, is a vascular-targeting drug. … [A233270] Literature demonstrates that NGR-peptides bind to a CD13 isoform, of which expression is restricted to tumor vasculature cells.

  5. Drug

    Ganirelix

    go.drugbank.com/drugs/DB06785
    ApprovedInvestigational

    Ganirelix is a synthetic decapeptide and a competitive gonadotropin-releasing hormone (GnRH) antagonist. Derived from endogenous GnRH, ganirelix has amino acid substitutions. … [L43045] The first case of pregnancy achieved after the use of ganirelix in an assisted reproduction program was reported in 1998.[A252195] Ganirelix was first approved by the FDA on July 29, 1999.

  6. Drug

    Prednicarbate

    go.drugbank.com/drugs/DB01130
    Approved

    Prednicarbate is a relatively new topical corticosteroid drug that displays a similar potency as [hydrocortisone]. … It has a favorable benefit-risk ratio, with an inflammatory action similar to that of a medium potency corticosteroid, but with a low potential to cause skin atrophy.

  7. Drug

    Pyrimethamine

    go.drugbank.com/drugs/DB00205
    ApprovedInvestigationalVet approved

    One of the folic acid antagonists that is used as an antimalarial or with a sulfonamide to treat toxoplasmosis.

  8. Drug

    Ubrogepant

    go.drugbank.com/drugs/DB15328
    ApprovedInvestigational

    [A189195] They appear to be better tolerated, do not contribute to medication overuse headaches, and carry no apparent cardiovascular risk, making them suitable for use in patients with cardiovascular … [L10959] Several oral small molecule CGRP receptor antagonists, belonging to a class of medications referred to as "gepants", have been investigated for migraines, but only ubrogepant and [rimegepant]

    Categories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates
  9. Drug

    Tetracaine

    go.drugbank.com/drugs/DB09085
    ApprovedInvestigationalVet approved

    Tetracaine is an ester local anaesthetic currently available in combination with lidocaine as a cream and patch.

  10. Drug

    Methsuximide

    go.drugbank.com/drugs/DB05246
    Approved

    Mesuximide (or methsuximide) is an anticonvulsant medication. It is sold by Pfizer under the name Petinutin.